Belite Bio (BLTE) Net Income towards Common Stockholders Growth (1y) (2023 - 2026)
Belite Bio (BLTE) Net Income towards Common Stockholders Growth (1y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -88.68% |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -58.11% |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 104.24% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -290.15% |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -129.68% |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -230.18% |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 59.59% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.59 Bn | 54.83 Bn | 3.31 Bn | -10.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -88.68% |
| Dec 31, 2025 | -150.73% |
| Sep 30, 2025 | -150.09% |
| Jun 30, 2025 | -71.90% |
| Mar 31, 2025 | 99.82% |
| Dec 31, 2024 | -144,392.13% |
| Sep 30, 2024 | -79,214.18% |
| Jun 30, 2024 | -39.37% |
| Mar 31, 2024 | -14.16% |
| Dec 31, 2023 | -3.05% |
| Sep 30, 2023 | 99.54% |
| Jun 30, 2023 | -184.90% |